Tests VERVE-102 in adults with high cholesterol or early heart artery disease
Tests VERVE-102, a gene-editing drug, in adults with familial high cholesterol.
Plain-language title generated from the registry record
Registry title: A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Key facts
- Where
- Chicoutimi, Hamilton, Montreal, Québec, Toronto, and Vancouver, CanadaSee the 6 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06164730, who can take part
Where in Canada
- Clinical Study CenterChicoutimi, CanadaTaking people
- Clinical Study CenterHamilton, CanadaTaking people
- Clinical Study CenterMontreal, CanadaTaking people
- Clinical Study CenterQuébec, CanadaTaking people
- Clinical Study CenterToronto, CanadaTaking people
- Clinical Study CenterVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Verve Therapeutics, Inc.
- Trial code
- NCT06164730
- Record updated
- 2 September 2026
- Original description
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.Read full original descriptionShow less
Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Inclusion: Diagnosis of HeFH or premature CAD.
Exclusion: Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe; Active or history of chronic liver disease; Clinically significant or abnormal laboratory values as defined by the protocol; Homozygous familial hypercholesterolemia.